Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical Trial

Reibaldi, Michele; Cardascia, Nicola; Longo, Antonio; Furino, Claudio; Avitabile, Teresio; Faro, Salvatore; Sanfilippo, M.; Russo, Andrea; Uva, Maurizio G.; Munno, Ferdinando; Cannemi, Vincenzo; Zagari, Marco; Boscia, Francesco

doi:10.1016/j.ajo.2009.08.026

Cited by 218 publications

(173 citation statements)

References 32 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…However, in spite of little discrepancy in the protocol, the success rate (about 83.3%) at 1 month on CSC is comparable with the previous outcomes (75-96%) after PDT. 13,14,[17][18][19]23 Our results of decreased choroidal thickness following PDT concur with prior reports. 13,14,16 It resulted from the action mechanism of PDT.…”

Section: Discussionsupporting

confidence: 83%

“…4,5,[17][18][19] Generally, in lowfluence PDT, a laser light at 689 nm delivered 25 J/cm 2 with an intensity of 300 mW/cm 2 over 83 s. 17,19 Whereas, in our study, the same wavelength laser with 600 mW/ cm 2 intensity as the full dose PDT was applied for 50 s and total light energy (30 J/cm 2 ). However, in spite of little discrepancy in the protocol, the success rate (about 83.3%) at 1 month on CSC is comparable with the previous outcomes (75-96%) after PDT.…”

Section: Discussionmentioning

confidence: 99%

“…To avoid the potential complications of conventional PDT, the patients had undergone a modified fluence PDT-reduced time of laser emission (50 s) and total light energy (30 J/cm 2 ), using the standard dose of verteporfin (6 mg/m 2 ) and laser intensity (600 mW/cm 2 ). 4,5,14,[17][18][19] The PDT spot size was determined by measuring the greatest linear dimension of the area of choroidal vascular hyperpermeability, corresponding to the origin of subfoveal fluid on ICGA. Patients receiving PDT were followed up and BCVA and SFCT using EDI-OCT at 7 day and 1 month after treatment were evaluated.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy

Kang

2013

Eye

View full text Add to dashboard Cite

Purpose To assess the change in subfoveal choroidal thickness (SFCT) in central serous chorioretinopathy (CSC) following spontaneous resolution and low-fluence photodynamic therapy (PDT) using the enhanced depth imaging optical coherence tomography (EDI-OCT). Methods A total of 36 consecutive eyes of 36 patients were included in this retrospective study: 16 eyes with spontaneously resolved CSC and 20 eyes with PDT-treated CSC. Best-corrected visual acuity and SFCT were evaluated at each visit until complete absorption of the subretinal fluid. SFCT of 32 normal subjects were also measured, as the control group. Wilcoxon's singed-rank test was used to evaluate the effects of spontaneous resolution and PDT. To compare the SFCT of the eyes with resolved CSC with that of the normal eyes, Mann-Whitney U-test with Bonferroni correction was also employed. Results SFCT of patients was 459.16 ± 77.50 lm at the baseline, and decreased to 419.31±54.49lm after a spontaneous resolution (P ¼ 0.015). However, SFCT was not normalized in comparison with that of the normal subjects (Po0.001). SFCT in PDT group was also reduced from 416.43 ± 74.01 to 349.50 ± 88.99 lm (Po0.001), with no significant difference with the normal value (P ¼ 0.087).Conclusions SFCT in patients with CSC decreased both after spontaneous resolution and low-fluence PDT. However, only in the PDT group, after disappearance of subretinal fluid, did it decrease to that of normal subjects.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy

Kang

2013

Eye

View full text Add to dashboard Cite

show abstract

“…15 Half-fluence PDT is as effective as standard-fluence PDT and may have the advantage of causing lower amount of choroidal hypoxia and nonperfusion over the standardfluence PDT. 16 A study by Kang and Kim 11 evaluating the choroidal thickness changes in spontaneously resolved CSC patients, and in patients treated with half-fluence PDT revealed that the mean choroidal thickness of CSC patients following PDT was similar to the healthy controls. However, in spontaneously resolved CSC patients, the decrease in choroidal thickness was not as much as the PDT-treated patients.…”

Section: Discussionmentioning

confidence: 99%

The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case–control study

Özkaya

Alkın

Özveren

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the resolution time and the recurrence rate of acute central serous chorioretinopathy (CSC) after spontaneous resolution and low-fluence photodynamic therapy (PDT). Methods Case-control study: The CSC patients who were admitted to our clinic for the first time were included. No treatment was given during the first 6 months. Patients were treated with PDT after 6 months from the initial signs of the disease, if they did not show any sign of resolution. The patients who showed a significant decrease in subretinal fluid after month 6 were not scheduled for PDT. The primary outcomes were the resolution time and the recurrence rate after the first episode. Secondary outcome measures were the change in BCVA and CRT during the follow up. Results A total of 77 consecutive eyes of 77 patients were included, 41 eyes (53.2%) with spontaneously resolved CSC and 36 eyes (46.8%) with PDT-treated CSC. The initial resolution time was 4.1 ± 3.2 months in spontaneous resolution group, and 8.1 ± 0.8 months in PDT group, respectively (Po0.001). The recurrence rate was 51.2% in spontaneous resolution group, and 25% in PDT group (P = 0.01). The change in BCVA from baseline to the last follow-up visit was statistically significant in both groups (P = 0.002, P = 0.003, respectively). The change in CRT from baseline to the last follow up was also statistically significant in both groups (P = 0.002, P = 0.003, respectively). Conclusions The recurrence rate of acute CSC was lower in PDT-treated patients than the spontaneously resolved patients.

show abstract

“…32 Nevertheless, PDT carries a potential risk for choroidal ischaemia, RPE atrophy, RPE rip, iatrogenic choroidal neovascularization, and vision loss, even with the generally preferred half-fluence settings. 1,[32][33][34][35][36][37] It has been shown that vascular endothelial growth factor (VEGF) levels are not elevated in patients with CSC, 38,39 and use of intravitreal anti-VEGF agents has been found inferior to PDT. 40 Therefore, these agents have a relatively minor and controversial role in the treatment of CSC.…”

Section: Discussionmentioning

confidence: 99%

Finasteride is effective for the treatment of central serous chorioretinopathy

Moisseiev

Holmes

Moshiri

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the safety and efficacy of finasteride treatment in patients with central serous chorioretinopathy (CSC). Methods Retrospective review of 29 eyes of 23 patients who were treated with finasteride for CSC. Previous medical and ocular history, steroid use, length of finasteride treatment, additional treatments for CSC, visual acuity (VA), central macular thickness (CMT), and presence of subretinal fluid (SRF) throughout the follow-up period, and the occurrence of any complications were recorded. Results Initial VA was 0.29 ± 0.31 logMAR, and a trend towards improved VA was noted after 3 months (0.25 ± 0.36 logMAR; P = 0.07). VA was significantly improved at the final follow-up (0.23 ± 0.27 logMAR; P = 0.024). Initial CMT was 354 ± 160 μm, and was significantly reduced after 1 month of treatment (284 ± 77 μm; P = 0.002) and this was maintained to the end of follow-up (247 ± 85 μm; P = 0.001). A significant reduction in SRF presence was found at all time points, with an overall 75.9% rate of complete resolution. Following discontinuation, SRF recurrence was noted in 37.5% of cases. No adverse events were recorded. Conclusions Finasteride is a safe and effective treatment for CSC. It may be a possible new option for the initial management of patient with CSC, and a suggested treatment approach is presented.

show abstract

Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical Trial

Cited by 218 publications

References 32 publications

Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy

Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy

The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case–control study

Finasteride is effective for the treatment of central serous chorioretinopathy

Contact Info

Product

Resources

About